open access

Vol 19, No 3 (2015)
Case report
Published online: 2015-09-29
Get Citation

The use of fixed dose combinations in the treatment of hypertension — resistant hypertension or patient resistant to treatment?

Rafał Ziemiński, Wojciech Rogala, Aleksandra Waszczuk, Grzegorz Dzida
DOI: 10.5603/AH.2015.0018
·
Arterial Hypertension 2015;19(3):140-144.

open access

Vol 19, No 3 (2015)
CASE REPORT
Published online: 2015-09-29

Abstract

Resistant hypertension (RH) is defined as a condition in which blood pressure remains above 140/90 mm Hg despite the use of at least three antihypertensive drugs, correctly combined and in full doses (including a diuretic). In Poland, the percentage of people suffering from RH is estimated at 10–13% relative to the total number of patients with hypertension. On the other hand, in recent years we have seen a significant increase in the importance of combination products both in Europe and in the United States. Several studies have shown that therapy that includes an average of 3 antihypertensive agents (in the form of combination products) having different mechanisms of action, such as blockers of the renin-angiotensin-aldosterone system (RAAS) in combination with a calcium channel blocker (CCB) or a diuretic, provides blood pressure control in the majority of patients, not only through increased efficacy and tolerability of drugs, but also owing to the simplification of the therapeutic regimen, which promotes the compliance with medical recommendations. In this paper we present the case of a patient with resistant hypertension, whose blood pressure normalised only after the use of a combination product.

Abstract

Resistant hypertension (RH) is defined as a condition in which blood pressure remains above 140/90 mm Hg despite the use of at least three antihypertensive drugs, correctly combined and in full doses (including a diuretic). In Poland, the percentage of people suffering from RH is estimated at 10–13% relative to the total number of patients with hypertension. On the other hand, in recent years we have seen a significant increase in the importance of combination products both in Europe and in the United States. Several studies have shown that therapy that includes an average of 3 antihypertensive agents (in the form of combination products) having different mechanisms of action, such as blockers of the renin-angiotensin-aldosterone system (RAAS) in combination with a calcium channel blocker (CCB) or a diuretic, provides blood pressure control in the majority of patients, not only through increased efficacy and tolerability of drugs, but also owing to the simplification of the therapeutic regimen, which promotes the compliance with medical recommendations. In this paper we present the case of a patient with resistant hypertension, whose blood pressure normalised only after the use of a combination product.

Get Citation

Keywords

resistant hypertension, combined therapy, calcium channel blocker

About this article
Title

The use of fixed dose combinations in the treatment of hypertension — resistant hypertension or patient resistant to treatment?

Journal

Arterial Hypertension

Issue

Vol 19, No 3 (2015)

Article type

Case report

Pages

140-144

Published online

2015-09-29

Page views

816

Article views/downloads

2300

DOI

10.5603/AH.2015.0018

Bibliographic record

Arterial Hypertension 2015;19(3):140-144.

Keywords

resistant hypertension
combined therapy
calcium channel blocker

Authors

Rafał Ziemiński
Wojciech Rogala
Aleksandra Waszczuk
Grzegorz Dzida

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl